NDV-01 — Interim data
YE 2026
Initial 3-month NDV-01 data from Phase 3 2L BCG-unresponsive study expected by YE 2026Source filing
RLMD biotech catalysts & pipeline
RELMADA THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
NDV-01 — NDA/BLA submission
Late 2026
We expect to file an United States Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) by year-end 2026.Source filing
sepranolone — NDA/BLA submission
Late 2026
We expect to file an IND application with the FDA by year-end 2026.Source filing